Posted On: 07/14/2016 1:05:19 PM
Post# of 72447
I disagree that the only pathway to a contract for the use in prosthetics is the antibiotic approval. This is from last September's 10-K:
"Other
In addition to their antimicrobial activity, we are evaluating the use of current and future host defense protein (HDP) mimics for disorders of barrier function,
where the innate immune system plays a vital role. For these disorders, the goal is to exploit the antiinflammatory and antibiofilm properties to restore and
maintain healthy skin and mucous membranes, and to treat refractory biofilmrelated infections on natural and artificial surfaces. This would include inflammatory or trauma-related conditions of the skin, eyes, GI tract, and respiratory mucosa; exacerbations of chronic bronchitis and cystic fibrosis; and infections of catheters, valves, and prosthetic joints."
It seems pretty clear that they desire all 3 properties for the potential JNJ usage.
As far as speed is concerned; B-OM may just be the fastest path for the moment to move B along. You may be correct that overall timeframe to approval may not be fastest with B-OM, but it might be the fastest path to strengthen the platform, demonstrate greater value, and help secure funding to expedite the phase 3 ABSSSI to the finish line. Hopefully the upcoming corporate update will expand upon the new strategy.
"Other
In addition to their antimicrobial activity, we are evaluating the use of current and future host defense protein (HDP) mimics for disorders of barrier function,
where the innate immune system plays a vital role. For these disorders, the goal is to exploit the antiinflammatory and antibiofilm properties to restore and
maintain healthy skin and mucous membranes, and to treat refractory biofilmrelated infections on natural and artificial surfaces. This would include inflammatory or trauma-related conditions of the skin, eyes, GI tract, and respiratory mucosa; exacerbations of chronic bronchitis and cystic fibrosis; and infections of catheters, valves, and prosthetic joints."
It seems pretty clear that they desire all 3 properties for the potential JNJ usage.
As far as speed is concerned; B-OM may just be the fastest path for the moment to move B along. You may be correct that overall timeframe to approval may not be fastest with B-OM, but it might be the fastest path to strengthen the platform, demonstrate greater value, and help secure funding to expedite the phase 3 ABSSSI to the finish line. Hopefully the upcoming corporate update will expand upon the new strategy.
(0)
(0)
